Jefferies cuts Zoetis to Hold as options buyers seek cover

A Jefferies downgrade and a fresh Goldman initiation at Neutral landed within four days of each other, pushing ZTS consensus squarely to Hold. The stock trades at $82, already below Jefferies' new $83 price target and well above Goldman's $74 entry point, leaving the mean street target at $93 with little conviction behind it.

Two desks, two bearish calls

Jefferies analyst Keith Devas cut ZTS from Buy to Hold on 20 October, slashing his price target from $103 to $83, a 19% reduction. That followed Goldman Sachs initiating coverage at Neutral with a $74 target on 16 October. Both actions arrived after a run of target-price cuts dating back to August, when seven firms trimmed forecasts following the Q2 print. TD Cowen and Citigroup both kept Buy ratings but cut targets to $94 and $96 respectively. JP Morgan's Overweight survives at $115, down from $130.

The consensus now reads 3 buys against 11 holds. At $82, the stock sits 12% below the mean target of $93, but the spread between Goldman's $74 floor and JP Morgan's $115 ceiling reflects genuine disagreement about where the animal health cycle goes next.

Options buyers reached for puts last week

On 19 October, the put-call ratio hit 0.53, two standard deviations above the 20-day mean. By 22 October it had pulled back to 0.45, below the 20-day mean of 0.47. The spike was brief but timed precisely with the Jefferies downgrade. The 52-week PCR range runs from 0.01 to 0.67, so 0.53 was elevated but not extreme.

The borrow market tells the opposite story

Despite the analyst pressure, short sellers are retreating from the stock. Short interest has fallen 16% over the past month to 3.9% of free float, and the borrow market reflects that exit. Cost to borrow has collapsed to 0.17%, down 52% in a week and 66% over the past month. Availability stands at 4,904% of short interest: roughly 338 million shares available to lend against 17 million currently borrowed. That is an exceptionally loose lending pool.

The stock is up 4.6% over the past week, while its closest peer, PAHC, gained 4.8% over the same period. ZTS has fallen roughly 37% year-to-date, so the recent bounce is recovery rather than trend.

What to watch

Zoetis reports on 3 November, eleven days away. Retail attention on the stock is running 1.74 standard deviations above its own 90-day average, per ORTEX Wikipedia and page-view data. The $83 Jefferies target and $74 Goldman target form the near-term reference range. A close above $83 before the print would put the Jefferies downgrade target in the rearview mirror. A miss that confirms the August trajectory would test Goldman's floor.

---

Data summary

• Price: $82.00, up 4.6% on the week
• Analyst consensus: Hold (3 buy, 11 hold); mean PT $93.00
• Recent actions: Jefferies Buy to Hold ($103 to $83); Goldman Neutral initiation ($74)
• SI % FF: 3.9%, down 16% over one month
• Cost to borrow: 0.17%, down 52% week-on-week
• Availability: 4,904% of short interest
• PCR: 0.45 (19 Oct spike: 0.53, +2.0 std dev above 20-day mean)
• Next earnings: 3 November 2026